Bishal Gyawali: This offers a good lesson on why oncology KOLs are not always the best person to interpret the results of a trial.

Quoting Bishal Gyawali, Associate Professor at Queen’s University, on LinkedIn:

“This is from FDA’s ODAC document re Codebreak 200 trial. This offers a good lesson on why oncology KOLs are not always the best person to interpret the results of a trial. Stop blindly following the KOLs or the guidelines and start thinking critically. When codebreak 200 results were published, some KOLs said sotorasib has now become the standard of care and that it beat docetaxel hands down. I had documented flaws with this trial back in April.”

Source: Bishal Gyawali/LinkedIn.